These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 17513819)

  • 21. Assessment of audit methodologies for bias evaluation of tumor progression in oncology clinical trials.
    Zhang JJ; Zhang L; Chen H; Murgo AJ; Dodd LE; Pazdur R; Sridhara R
    Clin Cancer Res; 2013 May; 19(10):2637-45. PubMed ID: 23532893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy.
    Zhuang SH; Xiu L; Elsayed YA
    Cancer J; 2009; 15(5):395-400. PubMed ID: 19826359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study.
    Chibaudel B; Bonnetain F; Shi Q; Buyse M; Tournigand C; Sargent DJ; Allegra CJ; Goldberg RM; de Gramont A
    J Clin Oncol; 2011 Nov; 29(31):4199-204. PubMed ID: 21969501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials?
    A'Hern RP
    J Clin Oncol; 2016 Oct; 34(28):3474-6. PubMed ID: 27507871
    [No Abstract]   [Full Text] [Related]  

  • 25. Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials.
    Driscoll JJ; Rixe O
    Cancer J; 2009; 15(5):401-5. PubMed ID: 19826360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On assessing the presence of evaluation-time bias in progression-free survival in randomized trials.
    Kay R; Wu J; Wittes J
    Pharm Stat; 2011; 10(3):213-7. PubMed ID: 20568099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Critical evaluation of disease stabilization as a measure of activity of systemic therapy: lessons from trials with arms in which patients do not receive active treatment.
    Le Tourneau C; Paoletti X; Coquan E; Sablin MP; Zoubir M; Tannock IF
    J Clin Oncol; 2014 Jan; 32(3):260-3. PubMed ID: 24297942
    [No Abstract]   [Full Text] [Related]  

  • 28. Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer.
    Ciani O; Buyse M; Garside R; Peters J; Saad ED; Stein K; Taylor RS
    J Clin Epidemiol; 2015 Jul; 68(7):833-42. PubMed ID: 25863582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of progression-free survival in oncology trials: some common statistical issues.
    Carroll KJ
    Pharm Stat; 2007; 6(2):99-113. PubMed ID: 17243095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer.
    Le Tourneau C; Michiels S; Gan HK; Siu LL
    J Clin Oncol; 2009 Dec; 27(35):5965-71. PubMed ID: 19805677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Do unblinded assessors bias muscle strength outcomes in randomized controlled trials of progressive resistance strength training in older adults?
    Liu CJ; LaValley M; Latham NK
    Am J Phys Med Rehabil; 2011 Mar; 90(3):190-6. PubMed ID: 21173683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endpoints in cancer clinical trials.
    Fiteni F; Westeel V; Pivot X; Borg C; Vernerey D; Bonnetain F
    J Visc Surg; 2014 Feb; 151(1):17-22. PubMed ID: 24440056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progression-free survival as an end-point in solid tumours--perspectives from clinical trials and clinical practice.
    Robinson AG; Booth CM; Eisenhauer EA
    Eur J Cancer; 2014 Sep; 50(13):2303-8. PubMed ID: 24974171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of discordance measures in oncology studies with blinded independent central review of progression-free survival using an observational error model.
    Mannino FV; Amit O; Lahiri S
    J Biopharm Stat; 2013; 23(5):971-85. PubMed ID: 23957510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measurement error in the timing of events: effect on survival analyses in randomized clinical trials.
    Korn EL; Dodd LE; Freidlin B
    Clin Trials; 2010 Dec; 7(6):626-33. PubMed ID: 20819840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure?
    Saad ED; Buyse M
    J Clin Oncol; 2012 May; 30(15):1750-4. PubMed ID: 22393092
    [No Abstract]   [Full Text] [Related]  

  • 37. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials.
    Saad ED; Katz A; Buyse M
    J Clin Oncol; 2010 Apr; 28(11):1958-62. PubMed ID: 20194852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of statistical issues with progression-free survival as an interval-censored time-to-event endpoint.
    Sun X; Li X; Chen C; Song Y
    J Biopharm Stat; 2013; 23(5):986-1003. PubMed ID: 23957511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statistics in oncology.
    Land SR; Abrams J; Buyse M; Chappell RJ
    J Clin Oncol; 2008 Aug; 26(22):3668. PubMed ID: 18669450
    [No Abstract]   [Full Text] [Related]  

  • 40. Endpoints for assessing drug activity in clinical trials.
    Pazdur R
    Oncologist; 2008; 13 Suppl 2():19-21. PubMed ID: 18434634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.